Fig 1

Analysis of 26 identified DRGs levels in TCGA data A:Expression levels of DRGs in gastric cancer tissues and adjacent non‑tumor tissues; B:Location of DRGs on chromosomes；C:CNV of DRGs in gastric cancer; D:SNV of DRGs in gastric cancer.

Fig 2

Construction of risk score model based on DRLncs in gastric cancer (DRG-RS) A: The top 8 prognostic DRLncs; B: Heat map showing the correlation between DRGs and LncRNAs; C: Path plots of the LASSO regression coefficients; D: Cross-validation curves of DRLs in the LASSO regression; E: Regression coefficient of Signature; F: PCA and t-SNE were used to analyze the distribution of high and low risk groups in the training set; G: PCA and t-SNE analysis of the validation set for the distribution of high and low risk groups.

Fig 3

Evaluation and validation of the independent prognostic ability of DRG-RS for gastric cancer A: The Kaplan-Meier (K-M) survival analysis of gastric cancer patients between high- and low-risk DRG-RS groups in the training set; B: The receiver ROC curves showed the predictive accuracy in 1-, 3-, and 5-year of the predictive risk model in the training set; C: The Kaplan-Meier (K-M) survival analysis of gastric cancer patients between high- and low-risk DRG-RS groups in the validation set; D: The ROC curves showed the predictive accuracy in 1-, 3-, and 5-year of the predictive risk model in the validation set; E: Univariate COX analysis and multivariate COX analysis of the training set; F: Univariate COX analysis and multivariate COX analysis of the validation set.

Fig 4

Construction of a nomogram combining clinical characteristics. A: The nomogram to predict the 1-, 3-, and 5-year overall survival (OS) rate of gastric cancer patients; B:) The calibration curve for evaluating the accuracy of the nomogram model in 1-, 3-, and 5-year categories; C: The time C-index curve of the Nomogram model; D: ROC curve of 1-year, 3-year and 5-year prognosis; E: ROC curve of the predictive power of the Nomogram model and clinicopathological parameters.

Fig 5

Analysis of DRG-RS related function A-C: GO enrichment analysis based on differential genes showed biological process (A: BP), cell component (B: CC) and molecular function (C: MF), respectively; D: KEGG pathway analysis based on differential genes; E: Heat map of tumor characteristic functional pathway activity.

Fig 6

Differences in DRG-RS across clinical subgroups A: Differences in DRG-RS among groups with tumor differentiation; B: Differences in DRG-RS among groups with tumor stage.

Fig 7

Responsiveness of the DRG-RS model to different drugs

Fig 8

LncRNA-SNHG4 promotes the proliferation and migration of gastric cancer cells A: The expression of LncRNA-SNHG4 in gastric cancer tissues was analyzed based on GEPIA; B: The expression of LncRNA-SNHG4 in gastric cancer tissues was analyzed based on gastric cancer samples; C: The correlation analysis between the expression of LncRNA-SNHG4 and tumor size in gastric cancer tissues; D: The correlation analysis between the expression of LncRNA-SNHG4 and tumor stage in gastric cancer tissues; E: Knockdown of LncRNA-SNHG4 in AGS cells inhibited the proliferation of gastric cancer cell; F:Overexpression of LncRNA-SNHG4 in AGS cells promoted the proliferation of gastric cancer cell; G: Knockdown of LncRNA-SNHG4 in AGS cells inhibited the migration of gastric cancer cells, while LncRNA-SNHG4 overexpression promoted the migration of gastric cancer cells.

Fig 9

LncRNA-SNHG4 promotes the activation of Wnt signaling pathway A:The expression of proteins associated with Wnt signaling pathway detected by Western Blotting in different groups; B: Statistical plot showed expression of the proteins associated with Wnt signaling pathway in different groups.